AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: NCT00535353
Drug: olaparib
RxNorm normalized name: Olaparib
DrugBank: Olaparib (DB09074)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: In Part A, a continuous oral AZD2281 dose will be given in combination with irinotecan given as a 90 minute infusion on day 1 every 21 days. In Part B, AZD2281 will be given on days 1-5 and irinotecan as a 90 minute infusion on day 3 each cycle. Cycles are repeated every 14 days.
Trial: NCT00090753
Drug: Methoxy Polyethylene Glycol-Epoetin Beta
RxNorm normalized name: Methoxy polyethylene glycol-epoetin beta
DrugBank: Methoxy polyethylene glycol-epoetin beta (DB09107)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Methoxy polyethylene glycol-epoetin beta was provided as a sterile single-use injectable solution in 2-mL glass vials containing 1 mL solution or in single-use sterile pre-filled syringes (PFSs) containing 0.3 mL or 0.6 mL injectable solution. The injectable solution was available in vials with the following strengths: 50, 100, 200, 400, and 1000 μg/mL. The injectable solution was available in PFSs with the following strengths: 30, 40, 50, 60, 75, 100, 120, 150, 200, and 250 μg/0.3 mL; and 360 and 400 μg/0.6 mL.
Trial: NCT00090753
Drug: Epoetin alfa
RxNorm normalized name: epoetin alfa
DrugBank: Erythropoietin (DB00016)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Epoetin alfa was provided with commercial packaging in English with country-specific labels (10,000 IU, 20,000 IU).
Trial: NCT00090753
Drug: Epoetin beta
RxNorm normalized name: Epoetin beta
DrugBank: Epoetin beta (DB19434)
FDA approved: no
EMA approved: yes
PMDA approved: no
Description: Epoetin beta was provided with commercial packaging in English with country-specific labels (50,000 IU, 100,000 IU).
Trial: NCT00090753
Drug: Darbepoetin alfa
RxNorm normalized name: Darbepoetin Alfa
DrugBank: Darbepoetin alfa (DB00012)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Darbepoetin alfa was provided with commercial packaging in English with country-specific labels (vials and PFSs in various strengths).
Trial: NCT01257191
Drug: Carbon Black
RxNorm normalized name: carbon black
DrugBank: Carbon black (DB11980)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: source: commercial
Trial: NCT01257191
Drug: Saline
RxNorm normalized name: Salinex
DrugBank: Sodium chloride (DB09153)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Saline solution
Trial: NCT00508898
Drug: Calcitriol
RxNorm normalized name: Calcitriol
DrugBank: Calcitriol (DB00136)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Patients will receive calcitriol (oral capsule) at a fixed dose of 1 mcg twice weekly.
Trial: NCT00508898
Drug: Multivitamin
RxNorm normalized name: multivitamin
DrugBank: Cyanocobalamin (DB00115)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Patients will receive multivitamin 1 tab daily (with vitamin D2 300 IU).
Trial: NCT01096745
Drug: Gemcitabine, Cisplatin
DrugBank: Gemcitabine (DB00441)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: D1,D8 Gemcitabine 1000mg/m2 + N/S 150cc miv over 30mins D1,D8 Cisplatin 25/m2 + N/S 150cc miv over 60mins repeated every 3weeks
Trial: NCT01096745
Drug: S-1, Cisplatin
DrugBank: Cisplatin (DB00515)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: D1-14 S-1 40mg/m2 po bid D1,D8 Cisplatin 25/m2 + N/S 150cc miv over 60mins Repeated every 3 weeks
Trial: NCT00605176
Drug: imiquimod cream
RxNorm normalized name: Imiquimod Cream
DrugBank: Imiquimod (DB00724)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: cream, 250 mg/packet, up to 2 packets applied daily for 2 treatment cycles. The first treatment cycle consisted of 2 weeks of daily treatment followed by 2 weeks of no treatment, and the second treatment cycle consisted of an additional 2 weeks of daily treatment followed by 8 weeks of no treatment.
Trial: NCT01115062
Drug: Synera Patch
RxNorm normalized name: lidocaine / tetracaine Medicated Patch [Synera]
DrugBank: Lidocaine (DB00281)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Synera Patch (lidocaine 70 mg/ tetracaine 70 mg) will be applied for 30 minutes to the venipuncture site
Trial: NCT01115062
Drug: LMX 4 Cream
DrugBank: Lidocaine (DB00281)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: LMX 4 (4% liposomal lidocaine) cream (2g) will be applied under Tegaderm for 30 minutes to the venipuncture site.
Trial: NCT01256060
Drug: Intranasal Oxytocin
RxNorm normalized name: Oxytocin
DrugBank: Oxytocin (DB00107)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: We are selecting morning and afternoon dosing to try to influence most hours where youth are in settings with increased potential for social interaction (school, after school). Medication will be administered by the parents before school and early afternoon. All patients will receive their first dose by the study physician to educate parents and themselves on proper administration and determine safety of first dose.
Trial: NCT00883116
Drug: Ixabepilone
RxNorm normalized name: Ixabepilone
DrugBank: Ixabepilone (DB04845)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT00883116
Drug: Paclitaxel
RxNorm normalized name: Paclitaxel
DrugBank: Paclitaxel (DB01229)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Trial: NCT02938520
Drug: Cabotegravir (CAB) tablet
RxNorm normalized name: cabotegravir Oral Tablet
DrugBank: Cabotegravir (DB11751)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: It is a white oval shaped film coated 30 mg tablets for oral administration. CAB Tablet is composed of cabotegravir sodium, lactose monohydrate, microcrystalline cellulose, hypromellose, sodium starch glycolate, magnesium stearate, and white film-coat.
Trial: NCT02938520
Drug: Rilpivirine (RPV) tablet
RxNorm normalized name: Rilpivirine
DrugBank: Rilpivirine (DB08864)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: It is a 25 mg tablet with off-white, round, biconvex, film-coated and debossed on one side with TMC and the other side with 25. Each tablet contains RPV hydrochloride, and the inactive ingredients croscarmellose sodium, lactose monohydrate, magnesium stearate, polysorbate 20, povidone K30 and silicified microcrystalline cellulose.
Trial: NCT04536792
Drug: AG-946
RxNorm normalized name: AGS-499
DrugBank: AGS-499 (DB18058)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: AG-946, oral encapsulated coated-granules or tablets.
Trial: NCT01467362
Drug: desonide 0.1% cream
DrugBank: Desonide (DB01260)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: cream, once a day (in the evening) during flares
Trial: NCT04461340
Drug: Sirolimus
RxNorm normalized name: Sirolimus
DrugBank: Sirolimus (DB00877)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: oral dose of 6 mg on day1 followed by 2 mg daily for 9 days
Trial: NCT01992874
Drug: Pimasertib Capsule (Part A)
RxNorm normalized name: Capivasertib
DrugBank: Pimasertib (DB14904)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pimasertib capsule administration at a single dose of 60 milligram (mg) orally on Day 1 in Part A.
Trial: NCT01992874
Drug: Pimasertib Tablet (Part A)
RxNorm normalized name: Capivasertib
DrugBank: Pimasertib (DB14904)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pimasertib tablet administration at a single dose of 60 mg orally on Day 3 in Part A.
Trial: NCT01992874
Drug: Pimasertib Tablet (Part A)
RxNorm normalized name: Capivasertib
DrugBank: Pimasertib (DB14904)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pimasertib tablet administration at a single dose of 60 mg orally on Day 1 in Part A.
Trial: NCT01992874
Drug: Pimasertib Capsule (Part A)
RxNorm normalized name: Capivasertib
DrugBank: Pimasertib (DB14904)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pimasertib capsule administration at a single dose of 60 mg orally on Day 3 in Part A.
Trial: NCT01992874
Drug: Pimasertib Capsule (Part B and trial extension phase)
RxNorm normalized name: Capivasertib
DrugBank: Pimasertib (DB14904)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subjects completing Part A to receive pimasertib capsule at a dose of 60 mg orally twice daily in cycles of 21 days each in Part B and trial extension phase until disease progression, intolerable toxicity, subject withdrawal, loss to follow-up or death.
Trial: NCT02698930
Drug: dexmedetomidine
RxNorm normalized name: Dexmedetomidine
DrugBank: Dexmedetomidine (DB00633)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Randomly selected patients of the dexmedetomidine group are given intravenous 0.4mcg/kg/h of dexmedetomidine from the beginning of the anesthesia to postoperative 1 day.
Trial: NCT02684396
Drug: TAK-648
RxNorm normalized name: TAK-243
DrugBank: TAK-243 (DB15013)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: TAK-648 Solution
Trial: NCT03888534
Drug: Ixazomib
RxNorm normalized name: Ixazomib
DrugBank: Ixazomib (DB09570)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Ixazomib intravenous injection in combination with reduction chemotherapy.
Trial: NCT00065117
Drug: 5-fluorouracil
RxNorm normalized name: 5-fluorouracil
DrugBank: Fluorouracil (DB00544)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT00065117
Drug: oxaliplatin
RxNorm normalized name: Oxaliplatin
DrugBank: Oxaliplatin (DB00526)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT04281524
Drug: CSL312
RxNorm normalized name: Immunoglobulin G4, anti-(human blood-coagulation factor viia) (human monoclonal CSL312 gamma4-chain), disulfide with human monoclonal CSL312 lambda-chain, dimer
DrugBank: Garadacimab (DB15629)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CSL312 administered as an IV infusion
Trial: NCT03904550
Drug: Cisatracurium + Neostigmine
RxNorm normalized name: Cisatracurium
DrugBank: Cisatracurium (DB00565)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Maintenance neuromuscular blockade with boluses of cisatracurium to keep train-of-four (TOF) 1-2 twitches. For reversal, neostigmine with glycopyrrolate
Trial: NCT04140292
Drug: Vitamin D3
RxNorm normalized name: Vitamin D3
DrugBank: Cholecalciferol (DB00169)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: D3 pills (10,000 IU each) to be taken daily at home, beginning at either day -5 or day -14, as per their assignment~Participants will receive a 5-day or 14-day supplementation of Vitamin D10,000 IU depending on their baseline Vitamin D 25 Hydroxy result
Trial: NCT03904550
Drug: Rocuronium + Sugammadex
DrugBank: Rocuronium (DB00728)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Maintenance neuromuscular blockade with boluses of rocuronium to keep TOF 1-2 twitches. For reversal, sugammadex
Trial: NCT01007409
Drug: Fimasartan
RxNorm normalized name: Fimasartan
DrugBank: Fimasartan (DB09279)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Period 1: administration of fimasartan 240mg at 9:00am, 30 minutes after the breakfast Period 2: administration of fimasartan 240mg at 9:00am, without the breakfast
Trial: NCT01007409
Drug: Fimasartan
RxNorm normalized name: Fimasartan
DrugBank: Fimasartan (DB09279)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Period 1: administration of fimasartan 240mg at 9:00am, without the breakfast Period 2: administration of fimasartan 240mg at 9:00am, 30 minutes after the breakfast
Trial: NCT02054754
Drug: Dexanabinol Dose Level 1
RxNorm normalized name: peanut allergenic extract
DrugBank: Dexanabinol (DB06444)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral formulation of dexanabinol
Trial: NCT02054754
Drug: Dexanabinol Dose Level 2
RxNorm normalized name: peanut allergenic extract
DrugBank: Dexanabinol (DB06444)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral formulation of dexanabinol
Trial: NCT02054754
Drug: Dexanabinol Dose Level 3
RxNorm normalized name: peanut allergenic extract
DrugBank: Dexanabinol (DB06444)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral formulation of dexanabinol
Trial: NCT02054754
Drug: Dexanabinol Dose Level 4
RxNorm normalized name: peanut allergenic extract
DrugBank: Dexanabinol (DB06444)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral formulation of dexanabinol
Trial: NCT02054754
Drug: Dexanabinol Dose Level 5
RxNorm normalized name: peanut allergenic extract
DrugBank: Dexanabinol (DB06444)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral formulation of dexanabinol
Trial: NCT02938520
Drug: Cabotegravir - Injectable Suspension (CAB LA)
RxNorm normalized name: cabotegravir Injection
DrugBank: Cabotegravir (DB11751)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: It is a sterile white to slightly pink suspension containing 200 mg/mL of CAB as free acid for administration by intramuscular (IM) injection. Each vial is for single-dose use containing a withdrawable volume of 2.0 mL, and does not require dilution prior to administration. CAB LA is composed of cabotegravir free acid, polysorbate 20, polyethylene glycol 3350, mannitol, and water for injection.
Trial: NCT02938520
Drug: Rilpivirine - Injectable Suspension (RPV LA)
RxNorm normalized name: rilpivirine Injection
DrugBank: Rilpivirine (DB08864)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: It is a sterile white suspension containing 300 mg/mL of RPV as the free base. The route of administration is by intramuscular (IM) injection. Each vial contains a nominal fill of 2.0 mL, and does not require dilution prior to administration. RPV LA requires refrigeration and must be protected from light. RPV LA is composed of RPV free base, poloxamer 338, sodium dihydrogen phosphate monohydrate, citric acid monohydrate, glucose monohydrate, sodium hydroxide, water for injection.
Trial: NCT00179673
Drug: Lenalidomide
RxNorm normalized name: Lenalidomide
DrugBank: Lenalidomide (DB00480)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Lenalidomide 25 mg orally once daily on Days 1 to 21 of every 28-day cycle for up to 52 weeks or until disease progression developed
Trial: NCT01269476
Drug: SNX-001
RxNorm normalized name: SNX-2112
DrugBank: SNX-2112 (DB17055)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 3.6, 7.2, or 10.8 mg single dose or t.i.w.
Trial: NCT01921335
Drug: ARRY-380 Twice Daily Dosage
RxNorm normalized name: clindamycin
DrugBank: Sage (DB10982)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: ARRY-380 will be administered daily (either twice-daily along with concurrent administration of trastuzumab on Day 1. PK sampling of ARRY-380 is planned on Day 15. Blood samples will be collected at pre-dosing, 2 hours (± 1 hour), and 6 hours (± 2 hours). The same time points will be collected for BID and QD schedules. On the PK collection day participants should fast one hour before and one hour after taking ARRY-380.
Trial: NCT01921335
Drug: Trastuzumab
RxNorm normalized name: trastuzumab
DrugBank: Trastuzumab (DB00072)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: 6 mg/kg IV every 3 weeks
Trial: NCT02292550
Drug: Ribociclib
RxNorm normalized name: Ribociclib
DrugBank: Ribociclib (DB11730)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: CDK 4/6 inhibitor
Trial: NCT02292550
Drug: Ceritinib
RxNorm normalized name: Ceritinib
DrugBank: Ceritinib (DB09063)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: ALK inhibitor
Trial: NCT02214706
Drug: Sirolimus
RxNorm normalized name: Sirolimus
DrugBank: Sirolimus (DB00877)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: sirolimus (40 µl) will be applied under occlusion, using van der Bend patch-test chambers (size: 1cm2), and left in situ for 7 days.
Trial: NCT01287715
Drug: etanercept
RxNorm normalized name: Etanercept
DrugBank: Etanercept (DB00005)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Discontinuation of etanercept (half of the dosis for 3 months and discontinuation thereafter)
Trial: NCT01287715
Drug: etanercept
RxNorm normalized name: Etanercept
DrugBank: Etanercept (DB00005)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Continuation of etanercept for another 9 months, and, if still meeting the eligibility criteria, discontinuation of etanercept thereafter.
Trial: NCT02243137
Drug: prasugrel
RxNorm normalized name: Prasugrel
DrugBank: Prasugrel (DB06209)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Administration: one loading dose (60mg)
Trial: NCT02990078
Drug: Sildenafil citrate
RxNorm normalized name: Sildenafil Citrate
DrugBank: Sildenafil (DB00203)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Sildenafil is a potent and specific PDE5 inhibitor, which was initially developed for the treatment of hypertension and angina. Its effectiveness as a treatment for male erectile dysfunction became apparent during Phase I clinical trials, and the focus of drug development shifted to this indication. In patients with cerebrovascular dysfunction, a few preliminary studies have used sildenafil to increase CVR. Participants in the pilot study had CVR tested in response to hypercapnia measured twice, at baseline and then 1 hour after administration of sildenafil citrate, 50 mg by mouth. The investigators have an IND exemption for the uses in this study.
Trial: NCT03267654
Drug: gefitinib combined with chemotherapy
DrugBank: Gefitinib (DB00317)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Gefitinib 250mg, p.o., q.d., continuous regimens on an empty stomach or after meal for 2 hours until disease progression, intolerable toxicity or patient withdraw ICF.~Pemetrexed (500mg/m²day 1 intravenously) plus carboplatin (AUC=5,day 1,intravenously) every 21 days. Every 3 weeks is a chemotherapy cycle, and 4 chemotherapy cycles is maximum limit.
Trial: NCT03267654
Drug: gefitinib combined with apatinib
DrugBank: Gefitinib (DB00317)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: gefitinib 250mg, p.o., q.d., continuous regimens on an empty stomach or after meal for 2 hours.~Apatinib 250mg, p.o., q.d. per 21 days. until disease progression, intolerable toxicity, patient withdraw ICF or death.
Trial: NCT03267654
Drug: gefitinib single agent
DrugBank: Gefitinib (DB00317)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Patients received Gefitinib 250mg q.d. orally until disease progression, intolerable toxicity or death.
Trial: NCT02241174
Drug: Sodium Hypochlorite
RxNorm normalized name: Sodium hypochlorite
DrugBank: Sodium citrate (DB09154)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: The 0.005% sodium hypochlorite solutions will be prepared from the commercially available Clorox® at 6% solution. 0.83ml of the 6% sodium hypochlorite solution will be taken and incorporated to a-100ml absolute distilled water. This 100ml solution will be stored in an amber glass bottle at room temperature unexposed to light at a maximum of 23 months
Trial: NCT03393741
Drug: Vinorelbine
RxNorm normalized name: Vinorelbine
DrugBank: Vinorelbine (DB00361)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Vinorelbine is a chemotherapeutic agent and a standard drug for treatment in breast cancer targeting microtubules. This drug is typically infused as a single agent for breast cancer therapy.
Trial: NCT03393741
Drug: Ixabepilone
RxNorm normalized name: Ixabepilone
DrugBank: Ixabepilone (DB04845)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Ixabepilone is a chemotherapeutic agent and a standard drug for treatment in breast cancer targeting microtubules. This drug is typically infused as a single agent for breast cancer therapy.
Trial: NCT03393741
Drug: Eribulin
RxNorm normalized name: Eribulin
DrugBank: Eribulin (DB08871)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Eribulin is a chemotherapeutic agent and a standard drug for treatment in breast cancer targeting microtubules. This drug is typically infused as a single agent for breast cancer therapy.
Trial: NCT00981227
Drug: Eslicarbazepine acetate
RxNorm normalized name: Eslicarbazepine Acetate
DrugBank: Eslicarbazepine acetate (DB09119)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Scored tablets
Trial: NCT00997126
Drug: Propofol
RxNorm normalized name: Propofol
DrugBank: Propofol (DB00818)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Propofol 1 mg/kg IV followed by 0.5 mg/kg prn sedation
Trial: NCT01609582
Drug: TAK-875
RxNorm normalized name: TAK-243
DrugBank: TAK-243 (DB15013)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: TAK-875 tablets
Trial: NCT00277160
Drug: Neulasta (pegfilgrastim)
RxNorm normalized name: pegfilgrastim Injection [Neulasta]
DrugBank: Pegfilgrastim (DB00019)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Commercial pegfilgrastim 6mg single subcutaneous fixed-dose
Trial: NCT04491695
Drug: Tirofiban Hydrochloride
RxNorm normalized name: Tirofiban Hydrochloride
DrugBank: Tirofiban (DB00775)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Tirofiban will use a loading dose, 0.4 μg/kg/min × 30 minutes, then 0.1μg/kg/min infusion for 71.5 hours.
Trial: NCT04491695
Drug: Oral antiplatelet
RxNorm normalized name: simethicone
DrugBank: Simethicone (DB09512)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Aspirin, clopidogrel or other antiplatelet drugs. Loading dose will be considered if the patients is not on antiplatelet therapy.
Trial: NCT00118365
Drug: eflornithine
RxNorm normalized name: Eflornithine
DrugBank: Eflornithine (DB06243)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Given orally
Trial: NCT00964873
Drug: STA-9090 (ganetespib)
RxNorm normalized name: Ganetespib
DrugBank: Ganetespib (DB12047)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Chemotherapy agent
Trial: NCT00051831
Drug: Emtricitabine
RxNorm normalized name: Emtricitabine
DrugBank: Emtricitabine (DB00879)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Will be administered as one 200-mg capsule orally daily
Trial: NCT00051831
Drug: Enfuvirtide
RxNorm normalized name: Enfuvirtide
DrugBank: Enfuvirtide (DB00109)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Will be administered as a 90-mg (1.0 mL) subcutaneous injection twice daily
Trial: NCT00051831
Drug: Ritonavir
RxNorm normalized name: Ritonavir
DrugBank: Ritonavir (DB00503)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Will be administered as one 100-mg capsule orally twice daily
Trial: NCT00051831
Drug: Saquinavir
RxNorm normalized name: Saquinavir
DrugBank: Saquinavir (DB01232)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Will be administered as five hard gel capsules orally twice daily
Trial: NCT01852578
Drug: Cabazitaxel
RxNorm normalized name: Cabazitaxel
DrugBank: Cabazitaxel (DB06772)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Cabazitaxel: 25 mg/m² i.v over 1 h on day 1. Cycles repeated ever 3 weeks
Trial: NCT00051831
Drug: Tenofovir disoproxil fumarate
RxNorm normalized name: Tenofovir Disoproxil Fumarate
DrugBank: Tenofovir disoproxil (DB00300)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Will be administered as one 300-mg tablet orally daily
Trial: NCT03067740
Drug: Bupivacaine
RxNorm normalized name: Bupivacaine
DrugBank: Bupivacaine (DB00297)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: intraperitoneal instillation of bupivacaine 0.25% ( 2mg/kg) after excision of the appendix.
Trial: NCT03067740
Drug: Dexmedetomidine
RxNorm normalized name: Dexmedetomidine
DrugBank: Dexmedetomidine (DB00633)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: intraperitoneal instillation of bupivacaine 0.25% ( 2mg/kg) plus dexmedetomidine 1mcg/kg after excision of the appendix.